Ceritinib

别名: LDK378 中文名称：

目录号：S7083 Purity: 99.96%

Ceritinib是一种有效的ALK抑制剂，在无细胞试验中IC50为0.2 nM。Ceritinib (LDK378)还可抑制IGF-1R、InsR、STK22D和FLT3对应的IC50值分别为8 nM、7 nM、23 nM和60 nM。Phase 3。

Ceritinib Chemical Structure

CAS: 1032900-25-6

规格	价格	库存
5mg	1182.86	现货
50mg	3868.47	现货
200mg	10720.71	现货
1g	23900	现货
更大包装有超大折扣
400-668-6834 info@selleck.cn

产品质控

批次：纯度： 99.96%

99.96

Ceritinib相关产品

相关产品	TAE684 (NVP-TAE684) GSK1838705A Repotrectinib (TPX-0005) AZD3463 AP26113-analog (ALK-IN-1) Ensartinib dihydrochloride ASP3026	点击展开
相关化合物库	激酶抑制剂库酪氨酸激酶抑制剂分子库 PI3K/Akt 抑制剂库细胞周期化合物库血管生成相关化合物库	点击展开

细胞实验数据示例

细胞系	实验类型	给药浓度	孵育时间	活性描述	文献信息
KARPAS299	Apoptosis assay	60 nM	24 hrs	Induction of apoptosis in human KARPAS299 cells harboring NPM-ALK at 60 nM after 24 hrs by acridine orange/ethidium bromide staining based fluorescence microscopic method	29174809
SU-DHL1	Function assay	20 to 200 nM	1 hr	Inhibition of ALK in human SU-DHL1 cells assessed as reduction in STAT3 phosphorylation at Y705 residue at 20 to 200 nM after 1 hr by Western blot analysis	29288940
SU-DHL1	Function assay	20 to 200 nM	1 hr	Inhibition of ALK phosphorylation at Y1278 residue in human SU-DHL1 cells at 20 to 200 nM after 1 hr by Western blot analysis	29288940
NCI-H3122	Function assay	20 to 200 nM	1 hr	Inhibition of ALK in human NCI-H3122 cells assessed as reduction in ERK phosphorylation at T202//Y204 residues at 20 to 200 nM after 1 hr by Western blot analysis	29288940
NCI-H3122	Function assay	20 to 200 nM	1 hr	Inhibition of ALK in human NCI-H3122 cells assessed as reduction in Akt phosphorylation at S473 residue at 20 to 200 nM after 1 hr by Western blot analysis	29288940
SU-DHL1	Function assay	20 to 200 nM	1 hr	Inhibition of ALK in human SU-DHL1 cells assessed as reduction in Akt phosphorylation at S473 residue at 20 to 200 nM after 1 hr by Western blot analysis	29288940
SU-DHL1	Function assay	20 to 200 nM	1 hr	Inhibition of ALK in human SU-DHL1 cells assessed as reduction in ERK phosphorylation at T202//Y204 residues at 20 to 200 nM after 1 hr by Western blot analysis	29288940
NCI-H3122	Function assay	20 to 200 nM	1 hr	Inhibition of ALK phosphorylation at Y1278 residue in human NCI-H3122 cells at 20 to 200 nM after 1 hr by Western blot analysis	29288940
NCI-H3122	Function assay	20 to 200 nM	1 hr	Inhibition of ALK in human NCI-H3122 cells assessed as reduction in STAT3 phosphorylation at Y705 residue at 20 to 200 nM after 1 hr by Western blot analysis	29288940
SU-DHL1	Function assay	30 nM	16 hrs	Inhibition of ALK autophosphorylation at Y1507 residue in human SU-DHL1 cells at 30 nM after 16 hrs by Western blot analysis	29627725
SU-DHL1	Function assay	30 nM	16 hrs	Inhibition of ALK in human SU-DHL1 cells assessed as reduction in STAT3 phosphorylation at Y705 residue at 30 nM after 16 hrs by Western blot analysis	29627725
NCI-H3122	Function assay	50 to 250 nM	16 hrs	Induction of ALK degradation in human NCI-H3122 cells assessed as decrease in ALK phosphorylation at Y1604 at 50 to 250 nM after 16 hrs by immunoblot method	29660984
KARPAS299	Function assay	50 to 250 nM	16 hrs	Induction of ALK degradation in human KARPAS299 cells assessed as decrease in ALK phosphorylation at Y1604 at 50 to 250 nM after 16 hrs by immunoblot method	29660984
KARPAS299	Apoptosis assay	50 nM	24 hrs	Induction of apoptosis in human KARPAS299 cells assessed as unclear cell shrinkage at 50 nM after 24 hrs by Hoechst 33258 staining based inverted fluorescence microscopy	30223120
KARPAS299	Apoptosis assay	50 nM	24 hrs	Induction of apoptosis in human KARPAS299 cells assessed as late apoptotic cells at 50 nM after 24 hrs by AO/EB double staining based inverted fluorescence microscopy	30223120
KARPAS299	Apoptosis assay	50 nM	24 hrs	Induction of apoptosis in human KARPAS299 cells assessed as fragmentation at 50 nM after 24 hrs by Hoechst 33258 staining based inverted fluorescence microscopy	30223120
Ba/F3 NA C1156Y	Growth Inhibition Assay		72 h	IC50=0.071 μM	25727400
Ba/F3 NA WT	Growth Inhibition Assay		72 h	IC50=0.020 μM	25727400
C1156F/D1203N 2809	Growth Inhibition Assay		72 h	IC50=254 ± 99 nM	25749034
E1210K 748	Growth Inhibition Assay		72 h	IC50=187 ± 84 nM	25749034
N1178H 169	Growth Inhibition Assay		72 h	IC50=42 ± 6 nM	25749034
F1174I 184	Growth Inhibition Assay		72 h	IC50=13 ± 0.1 nM	25749034
I1171T 445	Growth Inhibition Assay		72 h	IC50=82 ± 12 nM	25749034
I1171N 519	Growth Inhibition Assay		72 h	IC50=187 ± 87 nM	25749034
C1156F 1293	Growth Inhibition Assay		72 h	IC50=217 ± 115 nM	25749034
G1128S 1022	Growth Inhibition Assay		72 h	IC50=102 ± 38 nM	25749034
WT 70	Growth Inhibition Assay		72 h	IC50=21 ± 8 nM	25749034
Parental(+IL3)	Growth Inhibition Assay		72 h	IC50=1586 ± 173 nM	25749034
Ba/F3 NA L1196M	Growth Inhibition Assay		72 h	IC50=0.042 μM	25727400
Ba/F3 NA L1152R	Growth Inhibition Assay		72 h	IC50=0.288 μM	25727400
Ba/F3 NA G1202R	Growth Inhibition Assay		72 h	IC50=0.277 μM	25727400
Ba/F3 NA G1269A	Growth Inhibition Assay		72 h	IC50=0.019 μM	25727400
Ba/F3 NA S1206Y	Growth Inhibition Assay		72 h	IC50=0.037 μM	25727400
Ba/F3 EA WT	Growth Inhibition Assay		72 h	IC50=0.021 μM	25727400
Ba/F3 EA C1156Y	Growth Inhibition Assay		72 h	IC50=0.026 μM	25727400
Ba/F3 EA L1196M	Growth Inhibition Assay		72 h	IC50=0.019 μM	25727400
Ba/F3 EA L1152R	Growth Inhibition Assay		72 h	IC50=0.099 μM	25727400
Ba/F3 EA G1202R	Growth Inhibition Assay		72 h	IC50=0.467 μM	25727400
Ba/F3 EA G1269A	Growth Inhibition Assay		72 h	IC50=0.033 μM	25727400
Ba/F3 EA S1206Y	Growth Inhibition Assay		72 h	IC50=0.038 μM	25727400
BAF3	Antiproliferative assay		72 hrs	Antiproliferative activity against mouse BAF3 cells harboring EML4-ALK after 72 hrs by SRB or CCK8 assay, IC50 = 0.0107 μM.	29288940
NCI-H3122	Antiproliferative assay		72 hrs	Antiproliferative activity against human NCI-H3122 cells after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay, EC50 = 0.015 μM.	26568289
NCI-H2228	Growth inhibition assay		3 days	Growth inhibition of human NCI-H2228 cells after 3 days by luminescence-based CellTiter-Glo assay, IC50 = 0.015 μM.	29627725
SU-DHL1	Growth inhibition assay		3 days	Growth inhibition of human SU-DHL1 cells after 3 days by luminescence-based CellTiter-Glo assay, IC50 = 0.015 μM.	29627725
DFCI114	Antiproliferative assay		72 hrs	Antiproliferative activity against human DFCI114 cells expressing EML4-ALK G1269A mutant after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay, EC50 = 0.018 μM.	26568289
HCC78	Cytotoxicity assay		72 hrs	Cytotoxicity against human HCC78 cells harboring SLC34A2-ROS1 assessed as reduction in cell proliferation after 72 hrs by MTT assay, IC50 = 0.018 μM.	27474925
KARPAS299	Cytotoxicity assay		2 to 3 days	Cytotoxicity against human KARPAS299 cells after 2 to 3 days by luciferase reporter gene assay, IC50 = 0.0228 μM.	23742252
NCI-H3122	Function assay		72 hrs	Inhibition of EML4 fused ALK in human NCI-H3122 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay, CC50 = 0.025 μM.	27915169
BAF3	Function assay		2 to 3 days	Inhibition of NPM-fused ALK (unknown origin) expressed in mouse BAF3 cells after 2 to 3 days by luciferase reporter gene assay, IC50 = 0.026 μM.	23742252
KARPAS299	Antiproliferative assay		72 hrs	Antiproliferative activity against human KARPAS299 cells harboring NPM-ALK after 72 hrs by MTT assay, IC50 = 0.026 μM.	29174809
NCI-H2228	Antiproliferative assay		72 hrs	Antiproliferative activity against human NCI-H2228 cells harboring EML4-ALK after 72 hrs by MTT assay, IC50 = 0.026 μM.	30223120
KARPAS299	Cytotoxicity assay		72 hrs	Cytotoxicity against human KARPAS299 cells harboring NPM-ALK assessed as reduction in cell proliferation after 72 hrs by MTT assay, IC50 = 0.027 μM.	27474925
Ba/F3	Function assay		72 hrs	Inhibition of EML4-ALK S1206Y mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay, IC50 = 0.033 μM.	26568289
NCI-H3122	Function assay		72 hrs	Inhibition of EML4-ALK in human NCI-H3122 cells assessed as inhibition of cell proliferation after 72 hrs by SRB assay, CC50 = 0.038 μM.	26923695
NCI-H3122	Function assay		72 hrs	Inhibition of EML4-ALK in human NCI-H3122 cells assessed as inhibition of cell proliferation after 72 hrs by SRB assay, CC50 = 0.038 μM.	26923695
NCI-H3122	Function assay		72 hrs	Inhibition of EML4 fused ALK in human NCI-H3122 cells assessed as cell growth inhibition after 72 hrs by SRB assay, CC50 = 0.038 μM.	28385505
Ba/F3	Function assay		72 hrs	Inhibition of wild type EML4-ALK (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay, IC50 = 0.041 μM.	26568289
Ba/F3	Function assay		72 hrs	Inhibition of wild type EML4-ALK (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay, IC50 = 0.041 μM.	26568289
KARPAS299	Antiproliferative assay		72 hrs	Antiproliferative activity against human KARPAS299 cells harboring NPM-ALK after 72 hrs by MTT assay, IC50 = 0.041 μM.	30223120
BAF3	Antiproliferative assay		72 hrs	Antiproliferative activity against mouse BAF3 cells harboring EML4-ALK L1196M mutant after 72 hrs by SRB or CCK8 assay, IC50 = 0.0549 μM.	29288940
Ba/F3	Function assay		72 hrs	Inhibition of EML4-ALK G1269A mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay, IC50 = 0.057 μM.	26568289
HCC78	Antiproliferative assay		72 hrs	Antiproliferative activity against human HCC78 cells harboring SLC34A2-ROS1 after 72 hrs by MTT assay, IC50 = 0.058 μM.	29174809
HCC78	Antiproliferative assay		72 hrs	Antiproliferative activity against human HCC78 cells harboring SLC34A2-ROS1 after 72 hrs by MTT assay, IC50 = 0.058 μM.	30223120
Ba/F3	Function assay		72 hrs	Inhibition of EML4-ALK L1196M mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay, IC50 = 0.064 μM.	26568289
DFCI76	Antiproliferative assay		72 hrs	Antiproliferative activity against human DFCI76 cells expressing EML4-ALK L1152R mutant after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay, EC50 = 0.072 μM.	26568289
BA/F3	Function assay		72 hrs	Inhibition of ALK L1196M mutant in mouse BA/F3 cells assessed as inhibition of cell proliferation after 72 hrs by WST1 assay, CC50 = 0.075 μM.	26923695
BA/F3	Function assay		72 hrs	Inhibition of EML4 fused ALK L1196M mutant (unknown origin) expressed in mouse BA/F3 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay, CC50 = 0.075 μM.	27915169
BA/F3	Function assay		72 hrs	Inhibition of EML4 fused ALK (unknown origin) expressed in mouse BA/F3 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay, CC50 = 0.075 μM.	27915169
BAF3	Function assay		72 hrs	Inhibition of ALK L1196M mutant (unknown origin) expressed in mouse BAF3 cells assessed as cell growth inhibition after 72 hrs by WST-1 assay, CC50 = 0.075 μM.	28385505
KARPAS299	Antiproliferative assay		72 hrs	Antiproliferative activity against human KARPAS299 cells harboring NPM-ALK after 72 hrs by SRB or CCK8 assay, IC50 = 0.084 μM.	29288940
SMS-KCNR	Antiproliferative assay		72 hrs	Antiproliferative activity against human SMS-KCNR cells expressing EML4-ALK R1275Q mutant after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay, EC50 = 0.092 μM.	26568289
NCI-H3122	Antiproliferative assay		72 hrs	Antiproliferative activity against human NCI-H3122 cells after 72 hrs by SRB or CCK8 assay, IC50 = 0.096 μM.	29288940
NCI-H2228	Antiproliferative assay		72 hrs	Antiproliferative activity against human NCI-H2228 cells harboring EML4-ALK after 72 hrs by MTT assay, IC50 = 0.099 μM.	29174809
Ba/F3	Function assay		72 hrs	Inhibition of EML4-ALK F1174L mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay, IC50 = 0.101 μM.	26568289
NCI-H2228	Cytotoxicity assay		72 hrs	Cytotoxicity against human NCI-H2228 cells assessed as cell viability after 72 hrs by MTS assay, IC50 = 0.1026 μM.	25644671
LAN5	Antiproliferative assay		72 hrs	Antiproliferative activity against human LAN5 cells expressing EML4-ALK R1275Q mutant after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay, EC50 = 0.122 μM.	26568289
SU-DHL1	Antiproliferative assay		72 hrs	Antiproliferative activity against human SU-DHL1 cells harboring NPM-ALK after 72 hrs by SRB or CCK8 assay, IC50 = 0.122 μM.	29288940
Kelly	Antiproliferative assay		72 hrs	Antiproliferative activity against human Kelly cells expressing EML4-ALK F1174L mutant after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay, EC50 = 0.142 μM.	26568289
Ba/F3	Function assay		72 hrs	Inhibition of EML4-ALK C1156Y mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay, IC50 = 0.164 μM.	26568289
SH-SY5Y	Antiproliferative assay		72 hrs	Antiproliferative activity against human SH-SY5Y cells expressing EML4-ALK F1174L mutant after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay, EC50 = 0.186 μM.	26568289
BAF3	Antiproliferative assay		72 hrs	Antiproliferative activity against mouse BAF3 cells harboring CD74-ROS1 after 72 hrs by SRB or CCK8 assay, IC50 = 0.234 μM.	29288940
SK-N-SH	Antiproliferative assay		72 hrs	Antiproliferative activity against human SK-N-SH cells expressing EML4-ALK F1174L mutant after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay, EC50 = 0.303 μM.	26568289
BAF3	Function assay		2 to 3 days	Inhibition of TEL-fused insulin receptor (unknown origin) expressed in mouse BAF3 cells after 2 to 3 days by luciferase reporter gene assay, IC50 = 0.3195 μM.	23742252
SK-N-FI	Antiproliferative assay		72 hrs	Antiproliferative activity against human SK-N-FI cells expressing wild type EML4-ALK after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay, EC50 = 0.349 μM.	26568289
CHLA20	Antiproliferative assay		72 hrs	Antiproliferative activity against human CHLA20 cells expressing EML4-ALK R1275Q mutant after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay, EC50 = 0.363 μM.	26568289
Ba/F3	Function assay		72 hrs	Inhibition of EML4-ALK G1202R mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay, IC50 = 0.444 μM.	26568289
LAN1	Antiproliferative assay		72 hrs	Antiproliferative activity against human LAN1 cells expressing EML4-ALK F1174L mutant after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay, EC50 = 0.549 μM.	26568289
SK-N-BE(2)	Antiproliferative assay		72 hrs	Antiproliferative activity against human SK-N-BE(2) cells expressing wild type EML4-ALK after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay, EC50 = 0.593 μM.	26568289
Ba/F3	Function assay		72 hrs	Inhibition of EML4-ALK 1151Tins mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay, IC50 = 0.668 μM.	26568289
BAF3	Antiproliferative assay		72 hrs	Antiproliferative activity against mouse BAF3 cells harboring EML4-ALK G1202R mutant after 72 hrs by SRB or CCK8 assay, IC50 = 0.726 μM.	29288940
Ba/F3	Function assay		72 hrs	Inhibition of human EGFR del19/T790M/C797S mutant expressed in mouse Ba/F3 cells assessed as cell growth inhibition after 72 hrs by CellTiter-Glo assay, GI50 = 0.7805 μM.	29136465
SK-N-AS	Antiproliferative assay		72 hrs	Antiproliferative activity against human SK-N-AS cells expressing wild type EML4-ALK after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay, EC50 = 1.045 μM.	26568289
BAF3	Cytotoxicity assay		2 to 3 days	Cytotoxicity against mouse BAF3 cells after 2 to 3 days by luciferase reporter gene assay, IC50 = 2.477 μM.	23742252
Ba/F3	Function assay		72 hrs	Inhibition of EML4-ALK L1152R mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay, IC50 = 2.747 μM.	26568289
BA/F3	Cytotoxicity assay		72 hrs	Cytotoxicity against mouse BA/F3 cells assessed as cell viability after 72 hrs by MTS assay, IC50 = 5.512 μM.	26568289
SH-SY5Y	Antiproliferative assay		72 hrs	Antiproliferative activity against human SH-SY5Y cells after 72 hrs by CellTiter-Glo luminescent cell viability assay	29660984
CHLA20	Antiproliferative assay		72 hrs	Antiproliferative activity against human CHLA20 cells after 72 hrs by CellTiter-Glo luminescent cell viability assay	29660984
SH-SY5Y	Antiproliferative assay		72 hrs	Antiproliferative activity against human SH-SY5Y cells after 72 hrs in presence of ABCB1 inhibitor tariquidar by CellTiter-Glo luminescent cell viability assay	29660984
CHLA20	Antiproliferative assay		72 hrs	Antiproliferative activity against human CHLA20 cells after 72 hrs in presence of ABCB1 inhibitor tariquidar by CellTiter-Glo luminescent cell viability assay	29660984
NCI-H3122	Antiproliferative assay		72 hrs	Antiproliferative activity against human NCI-H3122 cells after 72 hrs by CellTiter-Glo luminescent cell viability assay	29660984
KARPAS299	Antiproliferative assay		72 hrs	Antiproliferative activity against human KARPAS299 cells after 72 hrs by CellTiter-Glo luminescent cell viability assay	29660984
SU-DHL1	Antiproliferative assay		72 hrs	Antiproliferative activity against human SU-DHL1 cells after 72 hrs by CellTiter-Glo luminescent cell viability assay	29660984
KARPAS299	Cytotoxicity assay			Cytotoxicity against human KARPAS299 cells expressing NPM-ALK fusion gene assessed as growth inhibition, IC50 = 0.0228 μM.	23837797
BA/F3	Cytotoxicity assay			Cytotoxicity against mouse BA/F3 cells expressing NPM-ALK fusion gene assessed as growth inhibition, IC50 = 0.026 μM.	23837797
NCI-H3122	Antiproliferative assay			Antiproliferative activity against wild type human NCI-H3122 cells, CC50 = 0.038 μM.	26235945
BA/F3	Function assay			Inhibition of ALK (unknown origin) transfected in mouse BA/F3 cells, IC50 = 0.0407 μM.	23837797
BAF3	Antiproliferative assay			Antiproliferative activity against mouse BAF3 cells expressing ALK L1196M mutant, CC50 = 0.075 μM.	26235945
BA/F3	Cytotoxicity assay			Cytotoxicity against mouse BA/F3 cells transfected with Tel-InsR gene assessed as growth inhibition, IC50 = 0.32 μM.	23837797
点击查看更多细胞系数据

生物活性

产品描述

特性

不与c-Met交叉反应，对体内葡萄糖稳态比TAE684效果好，有效作用于 Crizotinib复发的肿瘤。

靶点

ALK ^[1] (Cell-free assay)	Insulin Receptor ^[1] (Cell-free assay)	IGF-1R ^[1] (Cell-free assay)	STK22D ^[1] (Cell-free assay)	FLT3 ^[1] (Cell-free assay)
0.2 nM	7 nM	8 nM	23 nM	60 nM

体外研究(In Vitro)
体外研究活性	LDK378作用于Ba/F3-NPM-ALK和Karpas290细胞，具有显著的抗增殖活性，IC50分别为26.0 nM 和 22.8 nM,作用于Ba/F3-Tel-InsR 和Ba/F3-WT细胞，IC50分别为319.5 nM 和 2477 nM。^[1]
激酶实验	激酶分析
激酶实验	所有激酶使用杆状病毒表达技术表达为组氨酸或GST标签的融合蛋白，除了在大肠杆菌中产生的未标记的ERK2。在LabChip迁移实验中测量激酶活性。实验在30°C下进行60分钟。在有或无LDK378存在时，通过线性进展曲线，获得LDK378对酶活性的作用效果。
细胞实验	细胞系	Ba/F3-NPM-ALK, Ba/F3-Tel-InsR, Ba/F3-WT, Karpas299 细胞
	浓度	~100 μM
	孵育时间	2-3 天
	方法	表达荧光素酶的细胞与连续稀释的LDK378 或 DMSO 温育2-3天。荧光素酶的表达用来衡量细胞增殖/存活，使用Bright-Glo萤光素酶检测系统来评估。使用 XLFit软件获得 IC50值。
实验图片	检测方法	检测指标	实验图片	PMID
	Western blot	p-ALK / ALK / p-AKT / AKT / p-ERK / ERK pROS1 / ROS1 / pSTAT3 / STAT3		28425916
	Growth inhibition assay	Cell viability		29067644

体内研究(In Vivo)
体内研究活性	LDK378 用于降低形成反应代谢的可能性，在肝微粒体几乎检测不到谷胱甘肽（GSH）加合物的水平（<1％）。LDK378具有相对良好的代谢稳定性，中度抑制CYP3A4（Midazolam底物）和抑制hERG。LDK378处理动物，与肝脏血流量相比，具有低的血浆清除率（小鼠，大鼠，狗和猴），处理小鼠，大鼠，狗和猴的口服生物利用度都在55％以上。LDK378 处理Karpas299 和H2228 大鼠移植瘤模型，抑制肿瘤生长，诱导肿瘤衰退，这种作用具有剂量依赖性，体重没有降低。LDK378处理小鼠，剂量高达100 mg/kg，对胰岛素水平或血浆葡萄糖的利用无影响。^[1]
动物实验	Animal Models	携带 Karpas299/H2228肿瘤的 RNU裸鼠
	Dosages	~50 mg/kg
	Administration	口服饲喂

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
临床试验信息 (data from https://clinicaltrials.gov, updated on 2024-05-22)
NCT02450903	Completed	Non-Small-Cell Lung Cancer	Novartis Pharmaceuticals\|Novartis	August 21 2015	Phase 2
NCT02040870	Completed	Non-Small Cell Lung Cancer	Novartis Pharmaceuticals\|Novartis	March 7 2014	Phase 1\|Phase 2
NCT01950481	Completed	Normal Hepatic Function\|Impaired Hepatic Function	Novartis Pharmaceuticals\|Novartis	January 2014	Phase 1
NCT01772797	Completed	Anaplastic Lymphoma Kinase (ALK)\|Non-small Cell Lung Cancer	Novartis Pharmaceuticals\|Novartis	June 2013	Phase 1
NCT01685060	Completed	Non-Small Cell Lung Cancer	Novartis Pharmaceuticals\|Novartis	November 26 2012	Phase 2
NCT01634763	Completed	Tumors Characterized by Genetic Alterations in Anaplastic Lymphoma Kinase (ALK)	Novartis Pharmaceuticals\|Novartis	June 2012	Phase 1

参考文献
[1] Marsilje TH, et al. J Med Chem. 2013, Jun 6.

参考文献

[1] Marsilje TH, et al. J Med Chem. 2013, Jun 6.

化学信息&溶解度

分子量	558.14	分子式	C₂₈H₃₆ClN₅O₃S
CAS号	1032900-25-6	SDF	Download Ceritinib SDF
Smiles	CC1=CC(=C(C=C1C2CCNCC2)OC(C)C)NC3=NC=C(C(=N3)NC4=CC=CC=C4S(=O)(=O)C(C)C)Cl
储存条件(自收到货起)	3年-20°C粉状	储备液保存和期限建议分装储备液，避免反复冻融！	1年-80°C溶于溶剂
储存条件(自收到货起)	3年-20°C粉状	储备液保存和期限建议分装储备液，避免反复冻融！	1个月-20°C溶于溶剂

体外溶解度
批次：

DMSO : 4 mg/mL ( (7.16 mM) ；DMSO吸湿会降低化合物溶解度，请使用新开封DMSO)

Water : Insoluble

Ethanol : Insoluble

DMSO : 20 mg/mL ( (35.83 mM) ；DMSO吸湿会降低化合物溶解度，请使用新开封DMSO)

Ethanol : 3 mg/mL (5.37 mM)

Water : Insoluble

Ethanol : 5 mg/mL (8.95 mM)

DMSO : 3 mg/mL ( (5.37 mM) ；DMSO吸湿会降低化合物溶解度，请使用新开封DMSO)

Water : Insoluble

摩尔浓度计算器

体内溶解度
批次：

现配现用，请按从左到右的顺序依次添加，澄清后再加入下一溶剂

动物体内配方计算器

实验计算

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×

稀释计算器分子量计算器

动物体内配方计算器（澄清溶液）

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 μL 动物数量只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO + % + % Tween 80 + % ddH2O

%DMSO+ %

计算结果：

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于μL DMSO溶液（母液浓度mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取μL DMSO母液，加入μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入μL ddH₂O，混匀澄清。

体内配方配制方法：取μL DMSO母液，加入μL Corn oil，混匀澄清。

注意：1. 首先保证母液是澄清的；
2.一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

* 必填项

常见问题及建议解决方法

问题 1:
how to reconstitute the inhibitor for oral administration to mice?

回答：
You can resuspend LDK378 in 30% PEG400/0.5% Tween 80/5% propylene glycol and use the suspension for oral gavage feeding.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Ceritinib

产品质控

Ceritinib相关产品

相关信号通路图

细胞实验数据示例

生物活性

化学信息&溶解度

实验计算

技术支持

常见问题及建议解决方法